Summary
Eli Lilly and Novo Nordisk are developing new oral weight loss and diabetes drugs expected to be available in 2026. These drugs are designed to provide easier access and potential affordability compared to current injectable options.
Key Facts
- Eli Lilly and Novo Nordisk are creating pills for weight loss and type-2 diabetes.
- Novo Nordisk's new pill, similar to Wegovy, showed an average 13.6% weight loss in studies.
- Eli Lilly's orforglipron pill led to an average weight loss of 22.9 lbs over 72 weeks.
- Both pills showed improvements in cardiovascular risk and blood sugar control.
- The pills are easier to take as they require no food or water restrictions.
- The drugs will cost $150 a month, cheaper than current prices, due to a deal with President Trump.
- Oral pills are regarded as more user-friendly compared to injectables.
